As the first agent to be approved for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA
Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity...
Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease...
With an increasing prevalence, due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of...
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. Current standard of care fails to...
Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD). Current lipid-modifying therapies, including statins, ezetimibe,...
Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist, physicians, patients, and healthcare...
The highly genericized biguanides and sulfonylureas are, by far, the most heavily prescribed type 2 diabetes (T2D) drug classes. However, branded...
Obesity is arguably the most pressing public health issue in the United States with its chronic progression that is associated with both type 2...
Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and...
The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered be...
Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength. A significant unmet need exists for treatment that...
The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition between...
Hyperphosphatemia is a common complication in the later stages of chronic kidney disease (CKD). Sequelae can include hypocalcemia, disturbances in...
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key gout patient populations...
As the first agent to be approved for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA
Get content updates to your inbox
Subscribe